Answers are grounded in this paper and cite their sources.
There is now compelling preclinical data demonstrating BET inhibition as a strategy to target processes known to be involved in disease development and progression with clinical trials of two bona fide BET inhibitors now underway. Patent activity in this area is increasing with initial activity focused on variations to reported BET inhibitors and more recent patents disclosing novel chemotypes as BET inhibitors.
No takes yet. Share an insight, caveat, or question.
Garnier et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: